Opinion

Video

Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

Author(s):

Nihar Desai, MD, MPH,Nathan Wong, PhD

Experts discuss how knowledge of lipoprotein(a) (Lp[a]) levels can empower patients in managing atherosclerotic cardiovascular disease (ASCVD) risk factors, how providers can collaborate with patients on Lp(a) testing and risk management, the potential population-level value of improved ASCVD risk assessment, and how the National Lipid Association’s (NLA) recommendation for one-time Lp(a) testing may benefit health systems.

Video content above is prompted by the following:

  • How might knowledge of Lp(a) levels empower patients in their management of ASCVD risk factors?
  • How might providers partner with their patients with respect to Lp(a) testing and ASCVD risk management?
  • What value might improved ASCVD risk assessment and risk factor management offer on a population level, such as to a health care system?
  • The NLA recommends Lp(a) testing only once in a patient’s lifetime. How, if at all, might this frequency benefit health systems?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Merrill H. Stewart, MD
1 expert is featured in this series.
5 experts are featured in this series
Related Content
Cardiologist listening to patient's heart | Image credit: Space_Cat – stock.adobe.com
June 19th 2025

40% of Patients With Heart Failure Don’t See Cardiologist Annually, Increasing Risk of Death

Hayden E. Klein
Patients who see a cardiologist at least once a year are about 24% less likely to die in the following year.
Managed Care Cast
May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi
In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
CBD oils and hemp leaves | Image credit: Irina_Evva – stock.adobe.com
May 23rd 2025

CBD-Based Drug Shows No Heart Safety Risks in Patients With CVD or Risk Factors

Hayden E. Klein
A pharmaceutical-grade cannabidiol (CBD) product was shown to be safe in high-risk patients hospitalized with COVID-19, with no increased rate of cardiac side effects compared with placebo.
Managed care cast logo.
May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Doctor taking child's blood pressure | Image credit: romaset – stock.adobe.com
May 14th 2025

3 Maternal Risk Factors Linked to Elevated Offspring Blood Pressure

Hayden E. Klein
Offspring born to mothers with prepregnancy obesity, gestational diabetes, or hypertensive disorders of pregnancy had higher systolic and diastolic blood pressure levels than those born to mothers without these risk factors.
Nurse using stethoscope on older patient | Image credit: InsideCreativeHouse – stock.adobe.com
May 9th 2025

Is Frailty Index the Most Accurate Predictor of CVD?

Hayden E. Klein
A study comparing biological aging indicators found that Rockwood Frailty Index was a stronger predictor of cardiovascular disease (CVD) than leukocyte telomere length in adults without prior CVD.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo